Sophia von Martial1, Gesa Nippel2, Laura Schmidt2, Adel Sammain2, Andrea Schölermann2, Simone Presto2, Athanasios Tsianakas3. 1. Klinik für Dermatologie und Allergologie, Fachklinik Bad Bentheim, Am Bade 1, 48455, Bad Bentheim, Deutschland. 2. Beiersdorf AG, Unnastr. 48, 20245, Hamburg, Deutschland. 3. Klinik für Dermatologie und Allergologie, Fachklinik Bad Bentheim, Am Bade 1, 48455, Bad Bentheim, Deutschland. a.tsianakas@fk-bentheim.de.
Abstract
BACKGROUND: Guidelines generally recommend an adjuvant treatment with emollients for patients suffering from psoriasis. However evidence for this purpose is limited. PATIENTS AND METHODS: We performed a prospective observational study with an emollient containing 10% urea, ceramides, glycerin and glyceryl glucoside in patients suffering from mild to moderate psoriasis. The patients had to be stable for at least 12 weeks on prior antipsoriatic therapy including topical therapy, systemic treatment or phototherapy which was continued during the trial. RESULTS: A 4-week daily application of the emollient resulted in significant improvement regarding quality of life (measured by DLQI, Dermatology Life Quality Index) and clinical outcome (measured by local PASI, Psoriasis Area and Severity Index) among the treated patients. CONCLUSION: The trial results show that a daily adjuvant treatment with emollients can support a basic antipsoriatic therapy both in aspects of clinical efficacy and quality of life in mild to moderate patients suffering from psoriasis.
BACKGROUND: Guidelines generally recommend an adjuvant treatment with emollients for patients suffering from psoriasis. However evidence for this purpose is limited. PATIENTS AND METHODS: We performed a prospective observational study with an emollient containing 10% urea, ceramides, glycerin and glyceryl glucoside in patients suffering from mild to moderate psoriasis. The patients had to be stable for at least 12 weeks on prior antipsoriatic therapy including topical therapy, systemic treatment or phototherapy which was continued during the trial. RESULTS: A 4-week daily application of the emollient resulted in significant improvement regarding quality of life (measured by DLQI, Dermatology Life Quality Index) and clinical outcome (measured by local PASI, Psoriasis Area and Severity Index) among the treated patients. CONCLUSION: The trial results show that a daily adjuvant treatment with emollients can support a basic antipsoriatic therapy both in aspects of clinical efficacy and quality of life in mild to moderate patients suffering from psoriasis.
Entities:
Keywords:
Basic therapy; Clinical pictures; Emollients; Psoriasis Area and Severity Index; Quality of life
Authors: Alexander Nast; Lasse Amelunxen; Matthias Augustin; Wolf-Henning Boehncke; Corinna Dressler; Matthew Gaskins; Peter Härle; Bernd Hoffstadt; Joachim Klaus; Joachim Koza; Ulrich Mrowietz; Hans-Michael Ockenfels; Sandra Philipp; Kristian Reich; Thomas Rosenbach; Berthold Rzany; Martin Schlaeger; Gerhard Schmid-Ott; Michael Sebastian; Ralph von Kiedrowski; Tobias Weberschock Journal: J Dtsch Dermatol Ges Date: 2018-05 Impact factor: 5.584